Colorectal cancer Medical Services in China

Colorectal cancer (CRC) is a malignant neoplasm arising from the epithelial lining of the colon or rectum. It typically develops from precancerous adenomatous polyps through a stepwise accumulation of genetic and epigenetic alterations—most notably in the APC, KRAS, TP53, and mismatch repair (MMR) genes—culminating in uncontrolled cellular proliferation, invasion, and metastasis. The disease follows the well-established adenoma-carcinoma sequence in ~85% of sporadic cases; however, hereditary forms—including Lynch syndrome (hereditary non-polyposis colorectal cancer) and familial adenomatous polyposis (FAP)—account for 5–10% of diagnoses and confer significantly elevated lifetime risk. Globally, CRC is the third most commonly diagnosed cancer and the second leading cause of cancer-related death, with over 1.9 million new cases and nearly 935,000 deaths annually (GLOBOCAN 2022). In China, incidence has risen sharply over the past two decades—now exceeding 550,000 new cases per year—driven by urbanization, aging populations, and shifts toward Westernized diets high in red/processed meats, low in dietary fiber, and associated with sedentary lifestyles. Key modifiable risk factors include obesity, type 2 diabetes, heavy alcohol consumption, smoking, and long-term inflammatory bowel disease (e.g., ulcerative colitis or Crohn’s colitis). Non-modifiable risks encompass age (>50 years), personal or family history of CRC or advanced adenomas, and inherited syndromes. Early-stage CRC is often asymptomatic, underscoring the critical importance of screening—particularly fecal immunochemical testing (FIT), colonoscopy, and multi-target stool DNA tests. When symptoms emerge, they may include persistent changes in bowel habits (e.g., diarrhea, constipation, or narrowing of stool), rectal bleeding or blood in stool, unexplained abdominal discomfort or cramping, iron-deficiency anemia, unintentional weight loss, or fatigue. Diagnosis relies on endoscopic visualization with biopsy confirmation, supplemented by cross-sectional imaging (CT/MRI) and molecular profiling (e.g., MSI/MMR status, RAS/BRAF mutations) to guide prognosis and therapy. Treatment is multidisciplinary: localized disease is primarily managed with surgical resection (laparoscopic or robotic-assisted colectomy/low anterior resection); locally advanced or node-positive cases often require adjuvant chemotherapy (e.g., FOLFOX or CAPEOX); and metastatic disease may involve systemic therapy (chemotherapy, targeted biologics like anti-EGFR or anti-VEGF agents), immunotherapy (for MSI-H/dMMR tumors), and metastasectomy when feasible. Beyond survival, CRC profoundly impacts quality of life—physically (bowel dysfunction, stoma-related challenges, neuropathy), psychologically (anxiety, depression, body image concerns), socially (work disruption, caregiving burden), and economically (out-of-pocket costs, lost productivity). Survivorship care emphasizes surveillance colonoscopy, nutritional support, physical rehabilitation, and psychosocial counseling to mitigate long-term sequelae and optimize functional recovery.

Colorectal cancer (CRC) arises from the malignant transformation of epithelial cells lining the colon or rectum, typically evolving through a multistep process known as the adenoma-carcinoma sequence. While the precise initiating event remains heterogeneous, dysregulation of key cellular pathways—including WNT/β-catenin signaling, TGF-β growth inhibition, and DNA mismatch repair—is central to carcinogenesis. The most common cause is the accumulation of somatic mutations in oncogenes (e.g., KRAS, BRAF) and tumor suppressor genes (e.g., APC, TP53, SMAD4), often preceded by aberrant crypt foci and progressing through low-grade and high-grade dysplasia within adenomatous polyps. Approximately 70–80% of sporadic CRC cases originate from conventional adenomas; sessile serrated lesions (SSLs) account for an increasing proportion—particularly right-sided and MSI-high tumors—via the serrated neoplasia pathway involving BRAF mutation and CpG island methylator phenotype (CIMP). Chronic inflammation also serves as a potent driver: longstanding ulcerative colitis or Crohn’s colitis confers up to a 2.4-fold increased risk after 10 years of disease duration, with risk escalating cumulatively due to oxidative DNA damage, cytokine-mediated proliferation (e.g., IL-6, TNF-α), and impaired immune surveillance.

Triggers refer to acute or modifiable exposures that accelerate or unmask underlying susceptibility. These include recurrent episodes of antibiotic-induced gut microbiota dysbiosis—particularly depletion of butyrate-producing Firmicutes—which compromises epithelial barrier integrity and anti-inflammatory regulation. Acute dietary insults, such as high-dose heme iron ingestion (e.g., from processed red meat), generate cytotoxic aldehydes and N-nitroso compounds in the colonic lumen, inducing lipid peroxidation and RAS pathway activation. Other triggers encompass severe constipation with prolonged fecal stasis, leading to extended mucosal exposure to bacterial β-glucuronidase and secondary bile acids (e.g., deoxycholic acid), which promote DNA damage and proliferative signaling.

Established risk factors include advancing age (median diagnosis at 67 years), male sex (1.3-fold higher incidence), obesity (BMI ≥30 associated with 30% increased risk, mediated by adipokine dysregulation and insulin resistance), physical inactivity, smoking (dose-dependent; ≥20 pack-years increases risk by 18–25%), and heavy alcohol consumption (≥30 g/day ethanol elevates risk by ~40%, likely via acetaldehyde toxicity and folate metabolism disruption). Type 2 diabetes mellitus independently increases CRC risk by 30–40%, reflecting chronic hyperinsulinemia and IGF-1–driven mitogenesis.

Genetic factors underlie 5–10% of CRC cases. Hereditary syndromes include Lynch syndrome (MLH1, MSH2, MSH6, PMS2, or EPCAM germline mutations), responsible for 2–4% of all CRC and characterized by early-onset, proximal predominance, and microsatellite instability (MSI-H). Familial adenomatous polyposis (FAP), caused by APC gene mutations, leads to hundreds to thousands of colorectal adenomas by adolescence and near-universal CRC by age 40 without intervention. Other rarer syndromes include MUTYH-associated polyposis (biallelic MUTYH), polymerase proofreading–associated polyposis (POLE/POLD1), and hereditary mixed polyposis syndrome (GREM1 epigenetic dysregulation). Genome-wide association studies have identified over 140 common low-penetrance susceptibility loci (e.g., rs6983267 at 8q24), each contributing modestly to polygenic risk.

Environmental factors interact synergistically with host biology. Long-term exposure to air pollutants (PM2.5, NO2) correlates with increased CRC incidence, potentially via systemic inflammation and aryl hydrocarbon receptor activation. Dietary patterns are paramount: diets low in dietary fiber (<20 g/day), calcium, vitamin D, and folate—and high in processed meats, saturated fats, and refined carbohydrates—promote dysbiosis, endotoxemia, and procarcinogenic metabolite profiles. Conversely, habitual consumption of whole grains, cruciferous vegetables, and fermented dairy is associated with reduced risk. Geographic variation underscores environmental influence: CRC incidence is highest in industrialized nations (e.g., Hungary, South Korea, USA) and lowest in sub-Saharan Africa, implicating Western lifestyle factors rather than ethnicity alone. Finally, socioeconomic determinants—including limited access to screening, delayed care, and occupational exposures to asbestos or chlorinated solvents—contribute meaningfully to disparities in incidence and mortality.

Colorectal cancer (CRC) is a malignant neoplasm arising from the epithelial lining of the colon or rectum. As a leading cause of cancer-related morbidity and mortality worldwide, its clinical presentation varies significantly depending on tumor location (right-sided vs. left-sided/rectal), size, growth pattern (exophytic vs. infiltrative), and stage at diagnosis. Early detection remains critical, as localized disease carries a five-year survival rate exceeding 90%, whereas metastatic disease drops to approximately 14%. Symptoms are often insidious and nonspecific in early stages, contributing to diagnostic delays.

Early symptoms—typically present in Stage I or II disease—are frequently subtle and easily attributed to benign gastrointestinal conditions. Patients may report intermittent, mild abdominal discomfort or cramping, particularly in the lower abdomen or left iliac fossa for descending/sigmoid tumors. A persistent change in bowel habits lasting more than four weeks—such as new-onset constipation, increased stool frequency, or alternating diarrhea and constipation—may be the earliest recognizable sign. Notably, these changes lack associated systemic features like fever or weight loss. Some individuals experience a subjective sensation of incomplete evacuation (tenesmus), especially with distal lesions near the rectum or sigmoid colon. Mild, occult gastrointestinal bleeding may occur without visible blood; this manifests as iron-deficiency anemia on routine blood work—evidenced by microcytic hypochromic red cells, low serum ferritin, and elevated total iron-binding capacity—often in otherwise asymptomatic patients over age 50. Subtle fatigue or exertional dyspnea secondary to chronic anemia may be the sole presenting complaint in right-sided cancers, where bleeding tends to be slow and chronic rather than overt.

Typical symptoms emerge as the tumor enlarges or invades adjacent structures. Hematochezia—bright red or maroon blood mixed with stool—is highly suggestive of distal (left-sided or rectal) malignancy and warrants urgent evaluation. Melena may occur with proximal lesions if bleeding is substantial and transit time allows for hemoglobin degradation. Progressive, painless, partial large-bowel obstruction presents with colicky abdominal pain, abdominal distension, nausea, and obstipation; this is more common with annular, stenosing tumors in the sigmoid or splenic flexure. Rectal tumors may produce a palpable mass on digital rectal examination (DRE), accompanied by urgency, tenesmus, or a feeling of rectal fullness. In advanced local disease, patients may develop palpable abdominal masses, particularly in the right lower quadrant for cecal or ascending colon cancers.

Accompanying systemic symptoms reflect tumor burden or paraneoplastic phenomena. Unintentional weight loss (>5% body weight over six months) and persistent, unexplained fatigue are red-flag indicators of advancing disease. Low-grade fevers, night sweats, and anorexia may accompany locally advanced or metastatic CRC. Paraneoplastic syndromes, though rare, include dermatomyositis (characterized by heliotrope rash and proximal muscle weakness), acanthosis nigricans (velvety hyperpigmented skin folds), and migratory thrombophlebitis (Trousseau’s sign). Hypercalcemia may occur secondary to PTHrP secretion or bone metastases, manifesting as polyuria, confusion, or constipation.

Complications arise from local invasion, obstruction, perforation, or metastasis. Acute large-bowel obstruction is a surgical emergency, often requiring decompression and resection. Tumor perforation leads to peritonitis or localized abscess formation, presenting with acute abdominal pain, rebound tenderness, and leukocytosis. Fistulization—particularly colovesical or colocutaneous—may result in pneumaturia, fecaluria, or purulent wound drainage. Hemorrhage can be life-threatening, especially in anticoagulated patients. Metastatic complications include hepatic dysfunction (jaundice, ascites, coagulopathy), pulmonary involvement (cough, dyspnea, hemoptysis), osseous metastases (pathologic fractures, spinal cord compression), and brain metastases (headache, focal neurologic deficits). Iron-deficiency anemia may progress to symptomatic anemia requiring transfusion support.

Diagnosis relies on a multimodal approach. Colonoscopy with biopsy remains the gold standard for definitive histopathologic diagnosis and staging assessment; it enables visualization of lesion morphology, location, and extent, and permits targeted tissue sampling. Pre-colonoscopy laboratory evaluation includes complete blood count (to detect anemia), comprehensive metabolic panel (assessing liver function and electrolytes), and carcinoembryonic antigen (CEA) level—used primarily for post-treatment surveillance rather than screening. Computed tomography (CT) of the chest, abdomen, and pelvis is first-line for initial staging to evaluate lymphadenopathy, hepatic metastases, and extra-abdominal spread. For rectal cancers, high-resolution pelvic MRI is essential to assess circumferential resection margin (CRM) involvement, mesorectal fascia infiltration, and nodal status. Endorectal ultrasound (ERUS) provides complementary depth-of-invasion (T-stage) and nodal (N-stage) information for mid- and low-rectal tumors. Positron emission tomography–CT (PET-CT) is reserved for equivocal findings on conventional imaging or suspected recurrence.

Differential diagnosis must exclude both benign and malignant mimics. Benign causes of hematochezia include hemorrhoids (typically associated with straining and painless bleeding), anal fissures (sharp pain with defecation and streaked blood), diverticular disease (often acute, painless bleeding in older adults), and inflammatory bowel disease (IBD)—particularly ulcerative colitis or Crohn’s colitis—which may present with bloody diarrhea, urgency, and systemic inflammation. Ischemic colitis commonly affects elderly patients with cardiovascular risk factors and presents with acute abdominal pain followed by hematochezia; endoscopic findings show segmental mucosal edema and ulceration. Infectious colitis (e.g., Campylobacter, Shigella, C. difficile) usually features acute onset, fever, and leukocytosis, with resolution after appropriate antimicrobial therapy. Other malignancies to consider include primary gastrointestinal lymphoma (often bulky, non-obstructing, with prominent lymphadenopathy), carcinoid tumors (associated with flushing, diarrhea, wheezing in metastatic disease), and metastatic disease to the colon from extracolonic primaries (e.g., melanoma, breast, lung). Rarely, solitary rectal ulcer syndrome or radiation proctitis may mimic CRC clinically and endoscopically, necessitating biopsy for distinction. Accurate differentiation hinges on meticulous history, physical examination—including DRE and abdominal palpation—endoscopic evaluation with systematic biopsy, and appropriate cross-sectional imaging.

Colorectal cancer (CRC) is the third most commonly diagnosed malignancy and the second leading cause of cancer-related mortality worldwide. In the Department of Gastroenterology, management emphasizes early detection, risk stratification, and multimodal therapeutic integration. Treatment selection depends on tumor stage (per TNM classification), molecular profile (e.g., microsatellite instability [MSI], RAS/BRAF mutation status), patient performance status, comorbidities, and treatment goals—curative versus palliative.

Conservative (non-surgical) management is primarily indicated for select early-stage lesions and unresectable or metastatic disease. For localized T1 adenocarcinomas confined to the submucosa without high-risk features (lymphovascular invasion, poor differentiation, positive margins), endoscopic resection—including endoscopic mucosal resection (EMR) or endoscopic submucosal dissection (ESD)—is considered definitive conservative therapy. These minimally invasive techniques preserve colonic anatomy and function, with 5-year recurrence rates <5% in appropriately selected cases. In locally advanced rectal cancer (cT3–4 or N+), neoadjuvant chemoradiotherapy (nCRT) remains standard: typically 50.4 Gy radiation delivered over 5–6 weeks combined with concurrent 5-fluorouracil (5-FU) or capecitabine. This approach achieves pathologic complete response (pCR) in ~15–25% of patients, enabling organ-preserving 'watch-and-wait' strategies under rigorous endoscopic and MRI surveillance—avoiding radical surgery in carefully monitored responders.

Pharmacotherapy is central across all stages. Adjuvant chemotherapy (e.g., FOLFOX [5-FU, leucovorin, oxaliplatin] or CAPEOX [capecitabine + oxaliplatin]) is recommended for stage III and high-risk stage II CRC following curative resection, reducing recurrence risk by 30–40%. For metastatic CRC (mCRC), systemic therapy is the cornerstone. First-line regimens include doublets (FOLFOX or FOLFIRI [5-FU, leucovorin, irinotecan]) or triplets (FOLFOXIRI) ± biologic agents. Anti-EGFR monoclonal antibodies (cetuximab, panitumumab) are reserved for RAS/BRAF wild-type left-sided tumors; anti-VEGF agents (bevacizumab, aflibercept, ramucirumab) are agnostic to sidedness or mutational status. Immunotherapy has revolutionized care for MSI-H/dMMR mCRC: pembrolizumab or nivolumab ± ipilimumab yields durable responses in >40% of patients, with median progression-free survival exceeding 16 months. Targeted therapies such as encorafenib + cetuximab are approved for BRAF V600E-mutant CRC. Maintenance therapy (e.g., 5-FU/capecitabine ± bevacizumab) after induction improves tolerability without compromising efficacy.

Surgical resection remains the only potentially curative modality for non-metastatic CRC. Laparoscopic colectomy is now standard-of-care for colon cancer, offering equivalent oncologic outcomes to open surgery with reduced postoperative pain, shorter hospital stays (median 4–5 days), and faster return to baseline function. For rectal cancer, total mesorectal excision (TME) is mandatory to achieve negative circumferential resection margins (CRM). Low anterior resection (LAR) preserves the anal sphincter in mid- to upper-rectal tumors, while abdominoperineal resection (APR) is reserved for low-lying tumors involving the distal rectum or anal canal. Transanal total mesorectal excision (TaTME) and robotic-assisted platforms enhance precision in narrow pelvic anatomy, particularly for male or obese patients. In select cases of synchronous liver-limited metastases, simultaneous or staged resection (with or without perioperative chemotherapy) may achieve long-term survival in 30–50% of patients.

China offers distinct advantages in CRC management. First, nationwide endoscopic screening programs—especially in urban centers like Shanghai, Beijing, and Guangzhou—leverage high-volume, standardized colonoscopy with AI-assisted real-time polyp detection (e.g., EndoAngel), improving adenoma detection rates by up to 25%. Second, China’s robust generic drug ecosystem ensures rapid, affordable access to biosimilars (e.g., cetuximab and bevacizumab biosimilars approved since 2020) and oral fluoropyrimidines, reducing out-of-pocket costs by >60% compared with Western markets. Third, integrated multidisciplinary tumor boards (MDTs) are mandated in Grade III hospitals, ensuring coordinated input from gastroenterologists, surgical oncologists, medical oncologists, radiologists, and pathologists within 72 hours of diagnosis. Fourth, China leads globally in clinical trial enrollment for novel CRC therapeutics—accounting for ~35% of Asia-Pacific phase III trials—and offers early-access programs for breakthrough agents like KRAS G12C inhibitors (adagrasib) and dual checkpoint inhibitors. Finally, standardized national guidelines (CSCO and CSOG) harmonize evidence-based practice across tiers of care, minimizing regional disparities.

Post-treatment recovery requires structured, multidisciplinary support. Patients undergoing resection should initiate early mobilization (ambulation within 6–12 hours post-op) to reduce ileus and thromboembolic risk. Dietary advancement begins with clear liquids on postoperative day one, progressing to low-residue then regular diet by day five—fiber reintroduction is gradual to prevent bloating. For those with stoma, certified enterostomal therapists provide pre- and postoperative counseling, appliance fitting, and skin integrity management. Chemotherapy recipients require proactive symptom control: cryotherapy for oxaliplatin-induced neuropathy, dose-modified schedules for hematologic toxicity, and nutritional supplementation (vitamin B12, iron, folate) for anemia or malabsorption. Surveillance follows CSCO protocols: colonoscopy at 1 year post-resection (or 6 months if incomplete initial exam), then every 3 years if normal; CEA monitoring every 3 months for 2 years, then every 6 months through year 5; CT chest/abdomen/pelvis every 6–12 months for stage II–III disease. Psychosocial support—including oncology-certified counseling and peer-led survivorship groups—is integral, given the high prevalence of anxiety (32%) and depression (24%) in CRC survivors. Long-term lifestyle modification is strongly encouraged: ≥150 minutes/week moderate exercise, Mediterranean-style diet rich in whole grains and cruciferous vegetables, smoking cessation, and alcohol moderation (<1 drink/day)—each independently associated with 20–30% reduction in recurrence risk. With comprehensive, stage-adapted care, 5-year overall survival exceeds 90% for stage I, 75–85% for stage II, 60–70% for stage III, and 15–25% for stage IV disease—underscoring the critical importance of timely diagnosis and personalized intervention.